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etinopathy and the association with pegylated interferon and
ibavirin
. Farley ∗, A. Truong, T. Nguyen, W. Shum
Dr John Farley Inc, Vancouver, BC, Canada
Background: Treatment of hepatitis C (HCV) with Pegylated
nterferon and Ribavirin can result in a many adverse effects
ut ocular complications are considered rare, benign and usually
eversible which does not require the cessation of treatment regi-
en. It has been suggested that retinopathy in patients undergoing
reatment with Pegylated interferon are increase if a history of
ypertension is present. However, retinopathy can occur without
istory of hypertension.
Methods: Retrospective chart review of 4 individuals who
eveloped retinal complications during hepatitis C treatment with
egylated Interferon Alfa 2a and Ribavirin.
Results: 4 Males, average age 49.75±5.97 years. Ethnicities: 2
aucasian, 1 Vietnamese, 1 Aboriginal. We assessed for other co-
orbidities such as diabetes (1 was uncertain); hypertension, and
ypercholestrol were not a factor. 2 was genotype 2, 1 genotype 3,
nd 1 genotype 1. Rapid viral response with HCV RNA undetected
t week 4 was noted for 3 with genotype 2 or 3, and early viral
esponse with HCV RNA undetected at week 12 was noted for 1
ho had genotype 1. Fibrosis: 1 No Fibrosis, 1 Fibrosis Stage 2, 1
ibrosis Stage 3, and 1 did not complete a biopsy. Averages wait
ime from likely infected date to treatment 20 years. Average wait
ime from year diagnosed was 6.67 years. 2 likely acquired through
ntravenous drug use and 2were uncertainwho they acquiredHCV.
etinal complications occurred between weeks 14 and 26 of treat-
ent with average time of 21 weeks into treatment. Diagnoses
ntertained included blurry vision in both eyes to retinal hemor-
hage and atherosclerotic retinopathy.
Conclusion: Retinopathy in patients treated with Pegylated
nterferon Alfa 2a and Ribavirin is considered rare. However, rou-
ine follow up is essential for management on treatment. We
peculate that individuals with more severe disease may be more
ikely to develop retinopathy. More research should be completed
norder toevaluate this aspect.Multidisciplinarymanagementdur-
ng the course of treatment is essential towards identifying and
onitoring for side effects and treatment response.
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Hepatitis C treatment outcome with pegylated interferon alpha
2a/ribavirin in a real life Community-based setting
J. Farley ∗, A. Truong, T. Nguyen, W. Shum
Dr John Farley Inc, Vancouver, BC, Canada
Background:Hepatitis C virus (HCV) can be successfully treated
with Pegylated Interferon Alpha 2a and weight-based Ribavirin for
a duration of 24 or 48 weeks depending on the genotype. The
likelihood of response is determined by virological factors such
as genotypes, viral load, and host factors such as degree of liver
ﬁbrosis, ethnicity. This study based on real-life setting validates
published studies (usually based in tertiary-care/ academic insti-
tution settings) on the feasibility and efﬁcacy of treating HCV in
diverse community-based clinical populations.
Methods: Medical chart review of 389 patients who under-
went HCV therapy between January 2001 and September 2011
in a community-based clinical setting in British Columbia. Treat-
ment is based on current standard of care recommendations using
Pegylated intrferon alpha 2a and Ribavirin combination. However,
Ribavirin dose was usually higher than recommended in at least
50% of cases. Laboratory tests (requested but not necessarily done
by all patients): HCV RNA at weeks 0, 4, 12, 24, 48 (Non-Genotype
2 & 3) and 6 months post treatment completion. Deﬁnitions:
Rapid virological response (RVR) is achieved when HCV RNA is not
detected at week 4, early virological response (EVR) at week 12
of treatment and sustained virological response (SVR) at least 6
months after completion of treatment.
Results: Per protocol, 45 were discontinued: “adverse side
effects” (7): Myocardial Infarction (1), surgery (2). Two deceased.
Null response after week 12 (33), voluntary discontinuation due to
other reasons (1).
56 patients were excluded from SVR analysis: lost to follow up
(31), pending SVR (19), still on treatment (1), missing data (5).
76.6% (259/333) achieved SVR: genotype 1; 72.0% (126/175),
genotype 2; 89.7% (35/39), genotype 3; 82.6% (95/115), genotype
other; 75.0% (3/4). Of thosewith RVR determinations 92.8% (90/97)
achieved SVR, and with EVR 89.4% (193/216) had SVR.
GENOTYPE BY TREATMENT RESPONSE
GENOTYPE (N) RVR NO RVR EVR NO EVR ETR NO ETR SVR NO SVR
1 (175) 28 (19%) 119 99
(57.6%)
73 139
(79.9%)
35 126 (72%)49
2 (39) 19
(54.3%)
16 32
(82.1%)
7 36
(92.3%)
3 35
(89.7%)
4
3 (115) 49
(53.8%)
42 81
(77.1%)
24 109
(94.8%)
6 95
(82.6%)
20
OTHER (4) 1 (25%) 3 4 (100%) 0 4 (100%) 0 3 (75%) 1
Total 97 180 216 104 288 44 259 74
Fisher Exact P-Value 0.000 0.0003 0.001 0.033
SVR BY EARLY VIRAL
RESPONSE
RVR NO RVR EVR NO EVR
SVR 90
(92.8%)
123 193
(89.4%)
55
NO SVR 7 57
(31.7%)
23 49
(47.1%)
Fisher Exact P-Value 0.00 0.00
SVR BY RIBAVIRIN DOSE
MISSING <=1 1-1.5 >1.5
SVR 40
(75.5%)
69
(67.6%)
135
(84.4%)
15
(83.3%)
NO SVR 13 33 25 3
Fisher Exact P=0.006
Missing column was excluded for statistically analysis. Fisher Test, P=0.006. Overall
the effectiveness of Ribavirin dosage on SVR was statistically signiﬁcant predictor
of SVR.
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Conclusion: Consistent with published studies, SVR rates were
igher for genotypes 2 and 3 than genotype 1. RVR and EVR are
trong predictors for SVR. The actual dosages of ribavirin adminis-
eredandreceived, appears to correlatewith likelihoodof achieving
VR. Regular monitoring and followup is essential and recom-
ended.
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raraquara, the most virulent among all hantavirus
.T. Figueiredo1,∗, A. Martins Machado2, G. Mazzoni Campos2, G.
arcia de Figueiredo3, G. Sabino dos Santo Junior4, M. de Pádua2,
. Jabur Badra5, W. Marciel de Souza2
School ofMedicine of Ribeirao Preto, University of Sao Paulo, Ribeirao
reto, Brazil
School of Medicine University of São Paulo in Ribeirão Preto, Ribeirão
reto, SP, Brazil
School of Medicine University of São Paulo, Ribeirão Preto, SP, Brazil
School of Medicine University of São Paulo in Ribeirão Preto, Ribeirao
reto, SP, Brazil
School of Medicine - University of São Paulo in Ribeirão Preto,
ibeirão Preto, SP, Brazil
Background:Hantavirus pulmonary syndrome (HPS) is a health
roblem in Brazil because of encroachment of sprawling urban,
gricultural, and cattle-raising areas into habitats of subfamily Sig-
odontinae rodents, which serve as hantavirus reservoirs. From
993 thru 2012, ∼1450 cases of HPS with a case-fatality rate of
9% were reported in Brazil. A large amount of these cases were
aused by Araraquara virus (ARAV) harbored by Necromys lasiurus,
rodent that lives in cerrado (a savanna-like ecosystem) regions at
he southeastern and central plateau of Brazil.
Methods: This study included: analisys of HPSP patients,
urveillance for hantavirus infections in wild rodents, experimen-
al Necromys lasiurus infection by hantavirus, analysis of HPS fatal
ases in different regions of Brazil.
Results: SeventyHPS cases fromcerrado regionpresenteddysp-
ea (87%), fever (81%), coughing (44%), headache (34%), tachycardia
81%), low arterial blood pressure (56%), metabolic acidosis (57%),
ymphocytopenia (51%), hematocrit >45% (70%), leukocytosis with
eft deviation (67%), creatinine (51%) and urea (42%). Respiratory
nsufﬁciency, low arterial blood pressure and shock occurred after
4 to 48 hours after starting symptoms. The case fatality rate was
4.3%. High hematocrit and decreased platelet levels were signs
trongly suggestive of the disease. We have also captured 568
odents in cerrado area, Necromys lasiurus was the most abundant,
nd 12.2% of these animals had antibodies to hantavirus. There-
ore, onlyARAVwas detected infectingNecromys.Necromys lasiurus
xperimentally inoculated with Rio Mamore hantavirus (RMV- not
elated to human disease), by intradermic route, produced virus
nfection andRMVwas recovered from lung, heart, spleen, liver and
idney. Besides, the infected Necromys lasiurus started to eliminate
MV in the urine 3 days and in the feces 6 days after inoculation.
he animals eliminated virus in the excreta for at least 14 days,
uggesting that Necromys lasiurus is able to transmit hantavirus.nfectious Diseases 16S (2012) e2–e157
Conclusion: Seventy percent of Brazilian HPS cases occured in
Southern, South-Eastern andCentral-Plateau regions.However, the
case-fatality rate of HPS was signiﬁcantly higher in cerrado areas
of South-Eastern and Central-Plateau. ARAV causes severe HPS that
leads to the highest case-fatality rate in the Americas. Therefore,
ARAV is, probably, themost virulent among all hantavirusesworld-
wide.
http://dx.doi.org/10.1016/j.ijid.2012.05.196
Type: Poster Presentation
Final Abstract Number: 40.035
Session: Virology and Viral Infections (Non-HIV)
Date: Thursday, June 14, 2012
Time: 12:45-14:15
Room: Poster & Exhibition Area
A shorter time interval between ﬁrst and second dengue infec-
tions is associated with protection from clinical illness in a
prospective school-based cohort in Thailand
K. Anderson1, R.V. Gibbons2,∗, A.L. Rothman3, R. Berkelman4, T.P.
Endy5
1 Rollins School of Public Health, Atlanta, GA, USA
2 Armed Forces Research Institute of Medical Sciences, Bangkok,
Thailand
3 University of Rhode Island, Providence, RI, USA
4 Rollins School of Public Health, Atlanta, GA, USA
5 State University of New York at Syracuse, Syracuse, NY, USA
Background:Despite the strong associationbetween secondary
dengue (DENV) infections and dengue hemorrhagic fever (DHF),
the majority of secondary infections are asymptomatic or dengue
fever (DF). The determinants of the clinical severity of secondary
infections remain unclear, though some studies have suggested
a possible titer-dependent and time-dependent role of cross-
protective dengueDENV antibodies.We investigate the association
between the time interval separating sequential DENV infections
and clinical severity andwhether, among individualswith the same
interval between infections, there were immunological differences
that were associated with disease severity.
Methods:Weuseddata from twophases of a prospective cohort
study to detect asymptomatic and symptomatic DENV infections
in school-children in Kamphaeng Phet, Thailand, conducted from
1998 to 2002 and 2004 to 2007. Children who experienced at least
one DENV infection during their enrollment were selected as the
population for analysis.
Results: 1696 children had at least one DENV infection detected
during their enrollment and 268 of these children had two DENV
infections detected. A shorter time interval between the ﬁrst and
second DENV infections detected in the cohort was associated with
an increased probability of asymptomatic infection. The associa-
tion was strongest in children who were seronegative for DENV-1
– DENV-4 by hemagglutination inhibition (HI) assay at enrollment
(average interval separating sequential infections of 2.6 years for
DHF, 1.9 years for DF, and 1.6 years for asymptomatic infections,
p=0.01 by exact Wilcoxon rank statistic). In the ﬁnal model com-
bining time since ﬁrst observed infection and the magnitude of
the antibody response to ﬁrst infection, the highest probability of
being asymptomatic was observed in individuals who experienced
their second infection at shorter intervals after the ﬁrst infection
and with a higher titer HI antibody response generated to the ﬁrst
infection.
